|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1997-12-18
|
|
pubmed:abstractText |
Induction chemoradiotherapy followed by surgery may improve survival rates among patients with esophageal carcinoma. We designed a novel intense induction regimen with paclitaxel and high-dose hyperfractionated radiotherapy to maximize complete response rates.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-5223
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
114
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
811-5; discussion 816
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:9375611-Adenocarcinoma,
pubmed-meshheading:9375611-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9375611-Carcinoma, Squamous Cell,
pubmed-meshheading:9375611-Cisplatin,
pubmed-meshheading:9375611-Dose Fractionation,
pubmed-meshheading:9375611-Esophageal Neoplasms,
pubmed-meshheading:9375611-Esophagitis,
pubmed-meshheading:9375611-Female,
pubmed-meshheading:9375611-Fluorouracil,
pubmed-meshheading:9375611-Humans,
pubmed-meshheading:9375611-Male,
pubmed-meshheading:9375611-Middle Aged,
pubmed-meshheading:9375611-Paclitaxel,
pubmed-meshheading:9375611-Survival Rate
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
|
|
pubmed:affiliation |
Section of Thoracic Surgery, Massachusetts General Hospital, Boston 02114, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
